Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES) (FIDES)
Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy With Temozolomide (FIDES) - an Exploratory Pilot and Feasibility Trial
This study is for people (children and adults) with a rare and aggressive brain tumor called H3K27-altered diffuse midline glioma (DMG) located in the pons, a deep part of the brainstem. These tumors are very difficult to treat because they grow into surrounding brain tissue and cannot be fully removed with surgery. Most patients currently survive less than one year after diagnosis, and treatment options are limited.
Current standard treatment The usual treatment is radiotherapy, sometimes combined with a chemotherapy drug called temozolomide (TMZ). This combination may slightly improve outcomes, but it is often not very effective for tumors in the pons. One possible reason is that the blood-brain barrier (BBB)-a natural protective filter in the brain-may be especially strong in this area, making it harder for medicines to reach the tumor.
What this study is testing This study is exploring a new approach to help chemotherapy reach the tumor more effectively. It uses MRI-guided focused ultrasound (with the Exablate system) to temporarily and safely open the blood-brain barrier in the tumor area. This may allow more temozolomide to enter the tumor.
Study goal
The main goal is to find out:
- Whether this technique is safe
- Whether it may help slow tumor growth or extend survival
Who can join
- Adults and children aged 4 years and older
- Diagnosed with H3K27-altered pontine DMG
- Eligible for temozolomide after completing radiation therapy
The study will include 20 participants (about half children and half adults).
What participants will do
Participants will:
- Receive 6 cycles of temozolomide chemotherapy
- Undergo focused ultrasound blood-brain barrier opening on the first day of each cycle
- Have regular MRI scans and check-ups to monitor safety and tumor response
Each treatment cycle includes 5 days of chemotherapy followed by a rest period of 23 days.
What the study is measuring
Researchers will look at:
- Safety of the procedure and device
- How long patients live without tumor progression (progression-free survival)
- Overall survival
- Tumor response to treatment
- Whether the procedure is practical to use in clinical care
They will also compare results to data from previous patients in international brain tumor registries.
Why this study matters This study is testing whether temporarily opening the brain's natural barrier can help chemotherapy work better in a type of brain tumor that currently has very limited treatment options.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
-
Utrecht、荷兰、3584 CX
- UMC Utrecht
-
接触:
-
接触:
- Tom J. Snijders, MD, PhD
- 电话号码:+31 88 75 679 95
- 邮箱:fides@umcutrecht.nl
-
首席研究员:
- Tom J. Snijders, MD, PhD
-
Utrecht、荷兰、3584 CS
- Princess Maxima Center for Pediatric Oncology
-
接触:
- Dannis G. van Vuurden, MD, PhD
- 电话号码:+31 88 972 9736
- 邮箱:secretariaatneuro-onco@prinsesmaximacentrum.nl
-
接触:
-
首席研究员:
- Dannis G. van Vuurden, MD, PhD
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Age ≥ 4 years.
- Histologically/molecularly verified de novo pontine H3K27-altered diffuse midline glioma.
- Main localization ('center of mass') in the brainstem. NB: some degree of extension beyond the brainstem, e.g. cerebellar peduncles, is allowed.
- Karnofsky Performance Score (KPS) or Lansky Performance Score (LPS) of ≥ 70/ KPS or LPS 60 and WHO/ECOG performance status ≤ 2.
- ASA-score of I-III.
- Intention to treat with (TMZ chemo-) radiation and maintenance TMZ as per consensus of the local multidisciplinary tumor board.
- Feasible to schedule the first Exablate BBBO procedure preferably within 4-6 weeks, acceptably within 12 weeks, after successful completion of radiotherapy/ concomitant TMZ-chemoradiation, defined as completed treatment as planned without reported CTCAEv6.0 grade 3-4 toxicities or, in case of reported CTCAEv6.0 grade 3-4 toxicities, the toxicities must be resolved to grade 2 prior to inclusion.
- If on steroids, stable or decreasing dose for at least 7 days prior to inclusion.
- Able to attend all study visits.
- Able and willing to give informed consent or have a legal guardian who is able and willing to do so.
Exclusion Criteria:
- Previous or ongoing participation in other clinical trials with other than standard-of-care tumor-directed treatment(s) for H3K27-altered DMG.
- Multifocal or leptomeningeal metastasized disease. Multifocal disease is defined as multiple FLAIR-hyperintense lesions, separated by normal-appearing brain tissue, with or without gadolinium enhancement. Multiple enhancing regions within one continuous FLAIR lesion can be considered as unifocal disease.
- Signs/symptoms of elevated intracranial pressure (ICP) (e.g. headache, vomiting, impaired vision/papilledema, impaired consciousness), with corresponding radiographic findings on MRI at time of screening.
- Severe dysphagia with feeding tube dependency.
- Evidence of acute clinically significant intracranial hemorrhage. NB: minimal hemorrhagic foci without obvious related clinical symptoms will not serve as grounds for exclusion.
- Tumor not visible on any pre-therapy or post-radiation imaging.
- Presence of extracranial / intracranial structures (e.g. metal prostheses, implants, calcifications) on pre-treatment CT-scan/ MRI-scan, significantly interfering with acoustic impedance as per judgement of the researchers.
- Known co-occurring other malignancy that is progressing or has required active treatment within the past 3 years, with exception of: carcinomas in situ (CIS) and non-melanoma skin cancers.
- Patients with right-to-left, bi-directional or transient right-to-left cardiac shunts.
- Known LVEF < 40 or unstable hemodynamics.
- Severe hypertension, not adequately controlled with study compatible medication (Adults: RR systolic >180 and/ or RR diastolic >100; Children: >p95 + 12mmHg).
- History of bleeding disorder and/or coagulopathy.
- Treatment with anti-coagulant therapy.
- Severely impaired renal function; creatinine clearance <30 mL/ min.
- Subjects with significant liver dysfunction; Child Pugh classification C.
- Known diagnosis of active or untreated hepatitis B, hepatitis C, tuberculosis.
- Any other illness or medical condition that in the investigator's opinion precludes participation in this study.
- Pregnant or lactating women.
- Expected uncontrollable therapy non-compliance/ non-cooperation that is likely to interfere with the study procedure, as per judgement of the investigators.
- Head circumference ≤ 49 cm.
- Weight ≥ 135 kg.
- Patient ≥ 18 years old, who requires general anesthesia to undergo the Exablate BBBO procedure.
- Contra-indication for MRI procedures.
- Known sensitivity to gadolinium-based contrast agents.
- Known sensitivity to the resonator agent (perflutren; Luminity®).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:FUS-BBBO-mediated delivery of temozolomide
The Exablate Model 4000 Type 2 system is used to induce localized and temporary blood-brain barrier opening in adult and pediatric patients with H3K27-altered pontine DMG undergoing standard of care temozolomide chemotherapy.
|
FUS-BBB opening involves the application of acoustic energy at low frequencies from over 1000 individual transducers to induce localized and temporary blood-brain barrier disruption in patients.
FUS-BBBO will be applied during each temozolomide cycle.
其他名称:
Patients will undergo six standard-of-care cycles of temozolomide maintenance therapy.
Each cycle will be combined with FUS-BBBO.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Device and procedure related adverse events
大体时间:Up to 72 hours after each Exablate BBBO procedure
|
The number and severity of device and Exablate BBBO procedure related adverse events (CTCAE version 6.0), will be assessed based on radiographical and clinical parameters.
|
Up to 72 hours after each Exablate BBBO procedure
|
|
6-month progression-free survival (PFS6)
大体时间:From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.
|
Proportion of patients alive and progression-free at 6 months, based on standardized imaging criteria (e.g., RANO or RAPNO for DMG).
|
From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- UMC_Utrecht
- 2025-520814-78-00 (克蒂斯)
- NL-009201 (其他标识符:CCMO)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享时间框架
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.